Until Labs Secures $58 Million Series A, Total Funding Exceeds $100 Million for Organ Preservation

San Francisco-based Until Labs, a biotechnology company focused on reversible cryopreservation, recently announced a significant Series A funding round of $58 million. This latest investment brings the company's total funding to over $100 million to date, as it continues its mission to revolutionize organ transplantation and medical hibernation. "We’ve raised $100M+ to date, we are developing reversible cryopreservation for patients in need of donor organs, and we are hiring," Until stated in a recent social media post.

The $58 million Series A round was led by Founders Fund, with additional participation from Lux Capital and Field Ventures. This substantial capital injection is earmarked to expand Until Labs' multidisciplinary team, encompassing experts in chemistry, biology, mechanical engineering, electrical engineering, neuroscience, and surgery. The funds will also support the development of essential perfusion hardware, cryoprotective agents, and rewarming infrastructure.

Until Labs is pioneering organ-scale reversible cryopreservation, a technology designed to preserve donor organs for extended periods at low temperatures, making them viable for indefinite storage before rewarming for transplant. This innovation directly addresses a critical challenge in the organ transplant system, where organs like hearts, lungs, and livers are typically viable for only 4-12 hours, and kidneys for 24-36 hours. Thousands of organs are currently lost annually due to these narrow windows and logistical hurdles.

The company's long-term vision extends beyond organ preservation to building the medical infrastructure for "pausing biological time," with an ultimate goal of whole-body medical hibernation technology. Until Labs has progressed from initial research on neural slices to preserving preclinical model organs and is now actively testing its methods in large animal organs. This work aims to ensure that every donated organ with the potential to save a life can be utilized effectively.

As the company scales its efforts, it is actively recruiting new talent to join its team. The expansion of its workforce and operational capabilities is crucial for advancing its technology, which promises to provide transplant patients and surgeons with more flexibility, improve organ matching, and prevent the discard of viable organs due to time constraints.